GBA1 and Parkinson disease: These results have prompted Sanofi to initiate a double‐blind, placebo‐controlled study to assess the efficacy and safety of a glucosylceramide synthase inhibitor (GZ/SAR402671, venglustat) in PD patients carrying a GBA mutation (ClinicalTrials.gov identifier NCT02906020).83